Under construction – not a live service
Sign in
Taking people in FranceNo phase

Studying patients with high-risk kidney cancer that has not spread

Observes people with high-risk kidney cancer that has not spread after surgery.

Plain-language title generated from the registry record
Registry title: Identification and Description of Patients With High-risk Non Metastatic RCC

Key facts

Where
Bordeaux, FranceSee the site

Where in France

  • CHU BordeauxBordeaux, FranceTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital, Bordeaux
Trial code
NCT07753343
Record updated
7 August 2026
Original description
Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisionsRead full original descriptionShow less

Identification and Description of Patients With High-risk Non Metastatic RCC (UroCCR 127)

Renal cell carcinoma (RCC) is the 14th most common cancer worldwide. Surgery is the standard of care for localized RCC, however, the risk of recurrence varies widely among patients. Adjuvant pembrolizumab has been shown to improve outcomes after nephrectomy but is associated with substantial toxicity and high costs. This study uses real-world data from the French UroCCR-Chain registry to characterize the natural history, management, and outcomes of non-metastatic RCC in France, with the aim of informing adjuvant treatment decisions

Inclusion: Adult patients diagnosed with local RCC or high-risk locally advanced RCC,; Included in UroCCR register between 1st january 2014 and 31st december 2023,; Consenting to participate in UroCCR and UroCCR-Chain registers.

Exclusion: Patients with metastatic disease at inclusion,; Patients not linked between UroCCR and SNDS datasources,; Patients with hereditary RCC.

ClinicalTrials.gov NCT07753343